HELP

Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in

6-K - CYBIN INC. (0001833141) (Filer)

D - CYBIN INC. (0001833141) (Filer)

D - CYBIN INC. (0001833141) (Filer)

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took several weeks to start working—and didn't always help everyone. Today, drug developers are introducing a new wave of treatments designed to work faster, target different areas of the brain, and offer hope to people with treatment-resistant depression. Researchers are also exploring innovative approaches, including NMDA receptor therapies, orexin-targeting drugs, and other next-generation medicines that could significantly improve patient o

6-K - CYBIN INC. (0001833141) (Filer)

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 - - Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder ("MDD") has surpassed 88% enrollment and is on track for topline data readout in Q4 20262,3 - - HLP003 Phase 2 data demonstrated durability at 12 months following two 16mg doses, with 100% response and 71% remission based on a MADRS benchmark of ≤10, with remission rising to 100% based on recent peer benchmarks of ≤124,5 - - Reported topline results in Phase 2 signal detec

40-F - CYBIN INC. (0001833141) (Filer)

Issued on behalf of Helus Pharma™Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026.NEW YORK and TORONTO, June 26, 2026 /CNW/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule. Late-stage psychiatric trials are notoriously hard to fill, which is why a clean enrollment update is meaningful. On June 24, 2026, Helus Pharm

6-K - CYBIN INC. (0001833141) (Filer)

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce that it has closed its previously announced underwritten offering of 10,309,280 common shares in the capital of the Company (the "Common Shares") at an offering price of US$4.85 per Common Share for aggregate gross proceeds of US$50 million (the "Offering"). Cantor and Barclays acted as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets acted as lead managers for

SUPPL - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

FWP - CYBIN INC. (0001833141) (Subject)

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the "Common Shares") at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the "Offering"). Cantor and Barclays are acting as joint bookrunning managers for the Offering. Bloom Burton Securities Inc. and Lucid Capital Markets are acting as lead managers for the Offering.

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of HLP003 three weeks apart -  - Previously reported Phase 2 HLP003 results showed response and remission rates of 75% at week 18 and by the 12-month mark, response and remission rates improved to 100% and 71% respectively - - Previously granted Breakthrough Therapy Designation for HLP003 by the FDA - - Company remains on track

6-K - CYBIN INC. (0001833141) (Filer)

NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Amir Inamdar, Helus Pharma's Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference taking place June 15-16, 2026. The fireside chat will be available on demand beginning on Monday, June 15 at 7:00 a.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma's investor relations website. About Helus Phar

6-K - CYBIN INC. (0001833141) (Filer)

Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Eric So, Helus Pharma's Interim Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, taking place June 2-4, 2026. The fireside chat will be webcast live on Thursday, June 4, 2026, at 2:35 p.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Present

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

Eric So, Interim CEO, to appear on panel entitled "The Next Wave of Health Innovation," on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Eric So, Helus Pharma's Interim Chief Executive Officer, will be speaking at the 29th Annual Milken Institute Global Conference on a panel entitled "The Next Wave of Health Innovation." The Conference will take place May 3-6, 2026, at The Beverly Hilton & Waldorf Astoria in Los Angeles, and the panel will be held on Monday, May 4, 2026, at 2:30

6-K - CYBIN INC. (0001833141) (Filer)

Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced a collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions ("VETS") to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder ("MDD"), while expanding mental health aw